Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Advanced NSCLC in the Frail/Elderly: Podcast of Discussion with Drs. Hesketh and Kelly
Author
Howard (Jack) West, MD

The last of our three cases reviewing management issues in elderly and frail patients with lung cancer, as covered in a recent webinar discussion I had with experts Paul J. Hesketh from Lahey Clinic and Karen Kelly from Kansas University Medical Center, focuses on treatment of advanced/metastatic NSCLC. Drs. Hesketh and Kelly are two of the world experts in this field that so desperately needs more research and careful thought, given that the median age of patients newly diagnosed with lung cancer in the US is now just over 70, and about a third of patients are frail, but our studies primarily or exclusively include younger, healthy patients. In fact, the figures include the reference of a review article that Dr. Hesketh is just publishing now in the Journal of Thoracic Oncology on treating patients 80 and older with lung cancer (it appears online but hasn't appeared in the actual printed journal yet).

Here is the audio and video versions of the podcast, along with the figures and transcript.

adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-audio-podcast

adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-transcript

adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-figs

As always, we welcome your thoughts and comments.

This program was made possible by an educational grant from OSI Pharmaceuticals, who had no input in its content. We thank them for their support.

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora